Human CD4+ T cell response to human herpesvirus 6

Journal of Virology

Volumn 86, Issue 9, 2012, Pages 4776-4792

  Nastke, Maria D ^a,b   Becerra, Aniuska ^a   Yin, Liusong ^a   Dominguez Amorocho, Omar ^a   Gibson, Laura ^a   Stern, Lawrence J ^a   Calvo Calle, J Mauricio ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ARTICLE; CD4+ T LYMPHOCYTE; CELL LINE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSPOT ASSAY; HAPLOTYPE; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRION;

ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CROSS REACTIONS; CYTOKINES; EPITOPES, T-LYMPHOCYTE; HAPLOTYPES; HERPESVIRUS 6, HUMAN; HLA-DR1 ANTIGEN; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; PEPTIDES; PROTEIN MULTIMERIZATION; ROSEOLOVIRUS INFECTIONS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TISSUE DONORS; VIRAL LOAD;

HUMAN HERPESVIRUS 5; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7;

EID: 84861312490     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06573-11     Document Type: Article

References (87)

1. Ablashi D, Salahuddin SZ. 1992. Biology and strain variants, p 69-79. In Ablashi DV, Krueger GR, Salahuddin SZ (ed), Perspectives in medical virology, vol 4. Human herpesvirus-6: epidemiology, molecular biology and clinical pathology. Elsevier, Amsterdam, Netherlands.
2. Ahlqvist J, et al. 2005. Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes. J. Neurovirol. 11:384-394.
3. Andreoletti L, Leveque N, Boulagnon C, Brasselet C, Fornes P. 2009. Viral causes of human myocarditis. Arch. Cardiovasc. Dis. 102:559-568.
4. Appay V. 2004. The physiological role of cytotoxic CD4(+) T-cells: the holy grail? Clin. Exp. Immunol. 138:10-13.
5. Asano Y, et al. 1994. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics 93:104-108.
6. Aslan N, et al. 2006. Cytotoxic CD4 T cells in viral hepatitis. J. Viral Hepat. 13:505-514.
7. Bach JM, et al. 1998. Identification of mimicry peptides based on sequential motifs of epitopes derived from 65-kDa glutamic acid decarboxylase. Eur. J. Immunol. 28:1902-1910.
8. Balci DD, Peker E, Duran N, Dogramaci CA. 2009. Sulfasalazineinduced hypersensitivity syndrome in a 15-year-old boy associated with human herpesvirus-6 reactivation. Cutan. Ocul. Toxicol. 28:45-47.
9. Barcy S, Corey L. 2001. Herpes simplex inhibits the capacity of lymphoblastoid B cell lines to stimulate CD4+ T cells. J. Immunol. 166:6242-6249.
10. Betts MR, Koup RA. 2004. Detection of T-cell degranulation: CD107a and b. Methods Cell Biol. 75:497-512.
11. Calvo-Calle JM, Strug I, Nastke MD, Baker SP, Stern LJ. 2007. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog. 3:1511-1529.
12. Cameron TO, et al. 2002. Labeling antigen-specific CD4(+) T cells with class II MHC oligomers. J. Immunol. Methods 268:51-69.
13. Casazza JP, et al. 2006. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J. Exp. Med. 203:2865-2877.
14. Chang YL, Parker ME, Nuovo G, Miller JB. 2009. Human herpesvirus 6-related fulminant myocarditis and hepatitis in an immunocompetent adult with fatal outcome. Hum. Pathol. 40:740-745.
15. Dagna L, Santoro F, Lusso P. 2006. Biological features of HHV-6, p 59-75. In Krueger G, Ablashi D (ed), Perspectives in medical virology, vol 12. Human herpesvirus-6, 2nd ed: general virology, epidemiology and clinical pathology. Elsevier, Amsterdam, Netherlands.
16. Davis MM, Altman JD, Newell EW. 2011. Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. Nat. Rev. Immunol. 11:551-558.
17. Day CL, et al. 2003. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J. Clin. Invest. 112:831-842.
18. De Bolle L, Naesens L, De Clercq E. 2005. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin. Microbiol. Rev. 18:217-245.
19. De Bolle L, Van Loon J, De Clercq E, Naesens L. 2005. Quantitative analysis of human herpesvirus 6 cell tropism. J. Med. Virol. 75:76-85.
20. Dominguez G, et al. 1999. Human herpesvirus 6B genome sequence: coding content and comparison with human herpesvirus 6A. J. Virol. 73:8040-8052.
21. Donati D, et al. 2005. Variant-specific tropism of human herpesvirus 6 in human astrocytes. J. Virol. 79:9439-9448.
22. Doolan DL, et al. 2000. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J. Immunol. 165:1123-1137.
23. Drago F, Broccolo F, Rebora A. 2009. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J. Am. Acad. Dermatol. 61:303-318.
24. Flamand L, Gosselin J, Stefanescu I, Ablashi D, Menezes J. 1995. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation. Blood 85: 1263-1271.
25. Fogdell-Hahn A, et al. 2005. Co-purification of soluble membrane cofactor protein (CD46) and human herpesvirus 6 variant A genome in serum from multiple sclerosis patients. Virus Res. 110:57-63.
26. Fonseca SG, et al. 2006. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients. AIDS 20:2263-2273.
27. Fotheringham J, Jacobson S. 2005. Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease. Herpes 12:4-9.
28. Fox JD, Briggs M, Ward PA, Tedder RS. 1990. Human herpesvirus 6 in salivary glands. Lancet 336:590-593.
29. Glosson NL, Hudson AW. 2007. Human herpesvirus-6A and-6B encode viral immunoevasins that downregulate class I MHC molecules. Virology 365:125-135.
30. Gobbi A, et al. 1999. Human herpesvirus 6 (HHV-6) causes severe thymocyte depletion in SCID-hu Thy/Liv mice. J. Exp. Med. 189:1953-1960.
31. Gompels UA. 2009. Human herpesviruses 6 and 7, p 147-153. In Mahy BWJ, van RegenmortelMHV(ed), Desk encyclopedia of human and medical virology, 1st ed. Academic Press, Oxford, United Kingdom.
32. Gompels UA, et al. 1995. The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution. Virology 209:29-51.
33. Hall CB, et al. 1998. Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A. Clin. Infect. Dis. 26:132-137.
34. Hall CB, et al. 1994. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N. Engl. J. Med. 331: 432-438.
35. Hammer J, Takacs B, Sinigaglia F. 1992. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J. Exp. Med. 176: 1007-1013.
36. Hammer J, et al. 1993. Promiscuous and allele-specific anchors in HLADR-binding peptides. Cell 74:197-203.
37. Hemmer B, et al. 1999. Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat. Med. 5:1375-1382.
38. Isegawa Y, et al. 1999. Comparison of the complete DNA sequences of human herpesvirus 6 variants A and B. J. Virol. 73:8053-8063.
39. Jing L, et al. 2008. An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J. Virol. 82:7120-7134.
40. Koide W, et al. 1998. Activation of lymphocytes by HHV-6 antigen in normal children and adults. Viral Immunol. 11:19-25.
41. Komaroff AL. 2006. Is human herpesvirus-6 a trigger for chronic fatigue syndrome? J. Clin. Virol. 37(Suppl. 1):S39-S46.
42. Kumagai T, et al. 2006. Time course characteristics of human herpesvirus 6 specific cellular immune response and natural killer cell activity in patients with exanthema subitum. J. Med. Virol. 78:792-799.
43. Lacey SF, et al. 2005. Simultaneous reconstitution of multiple cytomegalovirus-specific CD8+ cell populations with divergent functionality in hematopoietic stem-cell transplant recipients. J. Infect. Dis. 191:977-984.
44. Lamb JR, Eckels DD, Lake P, Woody JN, Green N. 1982. Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin. Nature 300:66-69.
45. Lee AW, et al. 2011. Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels. Mol. Immunol. 48:1160-1167.
46. Levine PH, Jarrett R, Clark DA. 1992. The epidemiology of human herpesvirus-6, p 9-23. In Ablashi DV, Krueger GRF, Salahuddin SZ (ed), Perspectives in medical virology, vol 4. Human herpesvirus-6: epidemiology, molecular biology and clinical pathology. Elsevier, Amsterdam, Netherlands.
47. Mao YS, Lu CZ, Wang X, Xiao BG. 2007. Induction of experimental autoimmune encephalomyelitis in Lewis rats by a viral peptide with limited homology to myelin basic protein. Exp. Neurol. 206:231-239.
48. Markovic-Plese S, et al. 2005. High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J. Neuroimmunol. 169:31-38.
49. Martorelli D, et al. 2010. Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer. Int. Rev. Immunol. 29:371-402.
50. Merlo A, et al. 2010. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. J. Immunol. 184:5895-5902.
51. Mori Y, Yamanishi K. 2007. HHV-6A, 6B, and 7: pathogenesis, host response, and clinical disease, p 833-842. In Arvin A, et al (ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
52. Norris PJ, et al. 2004. Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells. AIDS Res. Hum. Retroviruses 20:315-325.
53. Ohyashiki JH, et al. 2005. Transcriptional profiling of human herpesvirus type B (HHV-6B) in an adult T cell leukemia cell line as in vitro model for persistent infection. Biochem. Biophys. Res. Commun. 329:11-17.
54. Panigada M, et al. 2002. Identification of a promiscuous T-cell epitope in Mycobacterium tuberculosis Mce proteins. Infect. Immun. 70:79-85.
55. Pourgheysari B, et al. 2007. The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J. Virol. 81:7759-7765.
56. Pourgheysari B, et al. 2009. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant. 43:853-861.
57. Precopio ML, et al. 2008. Optimizing peptide matrices for identifying T-cell antigens. Cytometry A 73:1071-1078.
58. Ressing ME, et al. 2008. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin. Cancer Biol. 18:397-408.
59. Salahuddin SZ, et al. 1986. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 234:596-601.
60. Salimi N, Fleri W, Peters B, Sette A. 2010. Design and utilization of epitope-based databases and predictive tools. Immunogenetics 62:185-196.
61. Schuler MM, Nastke MD, Stevanovikc S. 2007. SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol. Biol. 409:75-93.
62. Scriba TJ, et al. 2005. Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J. Immunol. 175: 6334-6343.
63. Shiley K, Blumberg E. 2010. Herpes viruses in transplant recipients: HSV, VZV, human herpes viruses, and EBV. Infect. Dis. Clin. North Am. 24: 373-393.
64. Soldan SS, Goodman AD, Jacobson S. 2006. HHV-6 and the central nervous system, p 213-223. In Krueger G, Ablashi D (ed), Perspectives in medical virology, vol 12. Human herpesvirus-6, 2nd ed: general virology, epidemiology and clinical pathology. Elsevier, Amsterdam, Netherlands.
65. Southwood S, et al. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160:3363-3373.
66. Stuller KA, Cush SS, Flano E. 2010. Persistent gamma-herpesvirus infection induces a CD4 T cell response containing functionally distinct effector populations. J. Immunol. 184:3850-3856.
67. Sturniolo T, et al. 1999. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 17:555-561.
68. Sylwester AW, et al. 2005. Broadly targeted human cytomegalovirusspecific CD4+and CD8+T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202:673-685.
69. Tejada-Simon MV, et al. 2002. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls. J. Virol. 76:6147-6154.
70. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. 2003. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann. Neurol. 53:189-197.
71. Tsao EH, et al. 2009. Microarray-based determination of the lytic cascade of human herpesvirus 6B. J. Gen. Virol. 90:2581-2591.
72. Uemura Y, et al. 2003. Systematic analysis of the combinatorial nature of epitopes recognized by TCR leads to identification of mimicry epitopes for glutamic acid decarboxylase 65-specific TCRs. J. Immunol. 170:947-960.
73. Van Vliet K, et al. 2009. Poxvirus proteomics and virus-host protein interactions. Microbiol. Mol. Biol. Rev. 73:730-749.
74. Vita R, et al. 2010. The immune epitope database 2.0. Nucleic Acids Res. 38:D854-D862.
75. Vollers SS, Stern LJ. 2008. Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 123: 305-313.
76. Waller EC, Day E, Sissons JG, Wills MR. 2008. Dynamics of T cell memory in human cytomegalovirus infection. Med. Microbiol. Immunol. 197:83-96.
77. Wang F, et al. 2006. Human herpesvirus-6-specific interleukin 10-producing CD4+ T cells suppress the CD4+ T-cell response in infected individuals. Microbiol. Immunol. 50:787-803.
78. Wertheimer AM, et al. 2003. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 37:577-589.
79. Whitley RJ, Lakeman FD. 2005. Human herpesvirus 6 infection of the central nervous system: is it just a case of mistaken association? Clin. Infect. Dis. 40:894-895.
80. Yakushijin Y, Yasukawa M, Kobayashi Y. 1992. Establishment and functional characterization of human herpesvirus 6-specific CD4+ human T-cell clones. J. Virol. 66:2773-2779.
81. Yakushijin Y, Yasukawa M, Kobayashi Y. 1991. T-cell immune response to human herpesvirus-6 in healthy adults. Microbiol. Immunol. 35:655-660.
82. Yamanishi K, et al. 1988. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet i:1065-1067.
83. Yamashita N, Morishima T. 2005. HHV-6 and seizures. Herpes 12: 46-49.
84. Yao K, Crawford JR, Komaroff AL, Ablashi DV, Jacobson S. 2010. Review part 2: human herpesvirus-6 in central nervous system diseases. J. Med. Virol. 82:1669-1678.
85. Yao K, Graham J, Akahata Y, Oh U, Jacobson S. 2010. Mechanism of neuroinflammation: enhanced cytotoxicity and IL-17 production via CD46 binding. J. Neuroimmune Pharmacol. 5:469-478.
86. Yao K, et al. 2006. Differential HHV-6A gene expression in T cells and primary human astrocytes based on multi-virus array analysis. Glia 53: 789-798.
87. Yasukawa M, Yakushijin Y, Furukawa M, Fujita S. 1993. Specificity analysis of human CD4+ T-cell clones directed against human herpesvirus 6 (HHV-6), HHV-7, and human cytomegalovirus. J. Virol. 67:6259-6264.